(NYSE:HIMS), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by […]

(NYSE:RDDT), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Reddit, Inc. (“Reddit” or the “Company”) (NYSE: RDDT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include

(NASDAQ:PLAB), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Photronics, Inc. (“Photronics” or the “Company”) (NASDAQ: PLAB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Photronics and certain of its officers and/or directors have engaged

(PinkSheets:RBGLY), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Reckitt Benckiser Group Plc (“Reckitt” or the “Company”)(OTCMKTS: RBGLY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to

(NASDAQ:TEM), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. (“Tempus” or the “Company”)(NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing

(NYSE:VSTS), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Vestis Corporation (“Vestis” or the “Company”) (NASDAQ: VSTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include

(NYSE:SOC), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Sable Offshore Corp. (“Sable” or the “Company”) (NYSE: SOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sable and certain of its officers and/or directors have

(NASDAQ:GILD), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Gilead and certain of its officers and/or directors have

(NasdaqGM:RCKT), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to

(NasdaqGM:URGN), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to